ECSP003371A - COMPOUNDS OF 1,2,3,4-TETRAHIDRO -1 -NAFTALENAMINA USEFUL IN THERAPY - Google Patents
COMPOUNDS OF 1,2,3,4-TETRAHIDRO -1 -NAFTALENAMINA USEFUL IN THERAPYInfo
- Publication number
- ECSP003371A ECSP003371A ECSP003371A ECSP003371A EC SP003371 A ECSP003371 A EC SP003371A EC SP003371 A ECSP003371 A EC SP003371A EC SP003371 A ECSP003371 A EC SP003371A
- Authority
- EC
- Ecuador
- Prior art keywords
- alkyl
- optionally substituted
- independently represent
- proviso
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La invención proporciona compuestos de la fórmula (I) (gráfico), en la que R1 y R2 representan independientemente H o alquilo C1-6; R3 representa fenilo sustituido con al menos un grupo seleccionado de entre halo, CF3, OCF3, CN,OH, alquilo C1-6 y alcoxi C1-6; y R4 y R5 y R11 representan independientemente H o -(CH2)n -A representando n 0,1 ó 2 con la condición de que al menos uno de R4 y R5 y R11 sea distinto de H; A representa CONR6R7 en los que SO2NR6R7, en los que R6 y R7 representan independientemente H, cicloalquilo C3-6 alquilo C1-6 estando el grupo alquilo C1-6 opcionalmente sustituido y además R6 y R7 junto con el átomo de N al que están unidos, representan un anillo que está opcionalmente sustituido; CO2R8 en el que R8 representa H o alquilo C1-6; NR9R10, en el que R9 y R10 representan independientemente H, alquilo C1-6; (opcionalmente sustituido), (alquilo C1-6) SO2-, (alquilo C1-6)CO-, H2NSO2- o H2NCO-; un anillo heterocíclico de 5 ó 6 miembros que contienen 1,2 ó 3 heteroátomos seleccionados entre N,S y O que está opcionalmente inhibidos S(O)x (alquilo C1-6) en el que X representa 0,1 ó 2; OH; CN; NO2; o alcoxi C1-6 que está opcionalmente sustituido, con la condición de que cuando NR1R2 representa N(H) metilo R4 representa H y R3 representa 4-clorefenilo, entonces R5 no representa metoxi; y sales farmacéuticamente aceptables del mismo. Los compuestos de la invención son útiles en el tratamiento o prevención de una diversidad de trastornos de monoamina con la condición de que cuandoThe invention provides compounds of the formula (I) (graph), wherein R1 and R2 independently represent H or C1-6 alkyl; R3 represents phenyl substituted with at least one group selected from halo, CF3, OCF3, CN, OH, C1-6 alkyl and C1-6 alkoxy; and R4 and R5 and R11 independently represent H or - (CH2) n -A representing n 0.1 or 2 with the proviso that at least one of R4 and R5 and R11 is different from H; A represents CONR6R7 in which SO2NR6R7, in which R6 and R7 independently represent H, C3-6 cycloalkyl C1-6 alkyl being the optionally substituted C1-6 alkyl group and furthermore R6 and R7 together with the N atom to which they are attached , represent a ring that is optionally substituted; CO2R8 in which R8 represents H or C1-6 alkyl; NR9R10, wherein R9 and R10 independently represent H, C1-6 alkyl; (optionally substituted), (C1-6 alkyl) SO2-, (C1-6 alkyl) CO-, H2NSO2- or H2NCO-; a 5 or 6 membered heterocyclic ring containing 1,2 or 3 heteroatoms selected from N, S and O that are optionally inhibited S (O) x (C 1-6 alkyl) in which X represents 0.1 or 2; OH; CN; NO2; or C1-6 alkoxy which is optionally substituted, with the proviso that when NR1R2 represents N (H) methyl R4 represents H and R3 represents 4-chlorephenyl, then R5 does not represent methoxy; and pharmaceutically acceptable salts thereof. The compounds of the invention are useful in the treatment or prevention of a variety of monoamine disorders with the proviso that when
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003371 ECSP003371A (en) | 2000-02-29 | 2000-02-29 | COMPOUNDS OF 1,2,3,4-TETRAHIDRO -1 -NAFTALENAMINA USEFUL IN THERAPY |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003371 ECSP003371A (en) | 2000-02-29 | 2000-02-29 | COMPOUNDS OF 1,2,3,4-TETRAHIDRO -1 -NAFTALENAMINA USEFUL IN THERAPY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP003371A true ECSP003371A (en) | 2001-09-24 |
Family
ID=42041002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP003371 ECSP003371A (en) | 2000-02-29 | 2000-02-29 | COMPOUNDS OF 1,2,3,4-TETRAHIDRO -1 -NAFTALENAMINA USEFUL IN THERAPY |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP003371A (en) |
-
2000
- 2000-02-29 EC ECSP003371 patent/ECSP003371A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR061053A1 (en) | NS5B INHIBITORS OF INDOLOBENZAZEPINE HEPATITIS C VIRUS FUSIONED TO CYCLOPROPYL | |
| AR057810A1 (en) | NS5B INDOLOBENZAZEPINE HCV INHIBITORS FUSIONED TO CYCLOPROPYL AND PHARMACEUTICAL COMPOSITION | |
| UY26727A1 (en) | USEFUL TROPANIC DERIVATIVES IN THERAPY | |
| AR041566A1 (en) | INDOL DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | |
| ES2259113T3 (en) | INHIBITORS OF FACTOR XA AND OTHER SERINPROTEASES INVOLVED IN THE COAGULATION WATERFALL. | |
| AR034282A1 (en) | DERIVATIVES OF DIFENYLAZETIDINONE, MEDICATIONS CONTAINING THESE COMPOUNDS, PROCEDURE FOR PREPARATION, AND ITS USE FOR THE PREPARATION OF MEDICINES | |
| AR035812A1 (en) | PHARMACEUTICALLY EFFECTIVE ACRILAMIDE COMPOUNDS AS INHIBITORS OF THE ENOIL-ACP REDUCTASA-FABI-; COMPOSITIONS FORMULATED WITH SUCH COMPOUNDS, METHOD FOR INHIBITING SUCH REDUCTION, RESPECTIVELY, TO TREAT BACTERIAL INFECTIONS USING SUCH COMPOUNDS AND USE OF THE COMPOUNDS MENCI | |
| AR045180A1 (en) | CHROME 3-AMINO AND 2-AMINO TETRALINA DERIVATIVES AND COMPOSITIONS CONTAINING THESE COMPOUNDS | |
| HUP0402376A2 (en) | Imidazole-4-carboxamide derivatives, their preparation and pharmaceutical compositions suitable for treatment of obesity containing them | |
| AR041260A1 (en) | PIPERAZINAS REPLACED BY HETEROCICLES FOR THE TREATMENT OF CHICHOPHRENIA | |
| AR050261A2 (en) | AMINO ACIDS AFFECTED BY THE ALFA-2-DELTA PROTEIN AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE TO PREPARE A MEDICINAL PRODUCT | |
| CY1106753T1 (en) | CARBAMIDE COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISORDERS | |
| NO20052976D0 (en) | Phosphodiesterase-4 inhibitors. | |
| AR039651A1 (en) | ISOQUINOLINE DERIVATIVES | |
| AR042362A1 (en) | DERIVATIVES OF 3H-QUINAZOLIN-4-ONA, PROCESS OF OBTAINING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| PE20030705A1 (en) | 17BETA-HYDROXIESTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN-DEPENDENT DISEASES | |
| AR056574A1 (en) | PIRAZOL DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND USE PROCEDURES | |
| AR054341A1 (en) | SYNERGIC COMBINATIONS OF FUNGICIDAL ACTIVE COMPOUNDS | |
| WO2004071389A3 (en) | Non-steroidal infalmmation inhibitors | |
| NO20050871L (en) | 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors | |
| ECSP003371A (en) | COMPOUNDS OF 1,2,3,4-TETRAHIDRO -1 -NAFTALENAMINA USEFUL IN THERAPY | |
| AR057464A1 (en) | PROCEDURE FOR THE PREPARATION OF SULFONAMIDE DERIVATIVES | |
| TW200510309A (en) | Chemical compounds | |
| EA200501136A1 (en) | TRIAZOLE COMPOUNDS USEFUL IN THERAPY | |
| CO5280088A1 (en) | PROTEASA INHIBITORS |